University of Miami

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr

Merck & Co. Inc. 's PD-1 inhibitor Keytruda (pembrolizumab) as a monotherapy is likely to get a more modest slice of the first-line lung cancer pie than some hoped for, following the release of deta

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar

A prolific partner for industry tapping into academic research, Johns Hopkins University has benefited from having a coordinated structure for deal-making that offers incubation and mentoring for